Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
Author:
Quiroga Borja1ORCID, Soler María José23ORCID, Ortiz Alberto34ORCID, Jaravaca Mantecón Carlos Jesús5, Nava Pérez Nathasha5, Serra Martín Marta6, Sato Yurika6, Marin Franco Antonio José7, Pazmiño Zambrano Diana Flor7, Lucena Valverde Rafael8, Ortega Diaz Mayra8, Calderón González Carmen9, Cazorla López Juan Manuel10, Pereira Mónica4, González Parra Emilio4, Sánchez Horrillo Ana1, Sánchez González Carmen1, Toapanta Néstor2ORCID, Cigarrán Guldris Secundino11ORCID, Sánchez Hernández Rosa12, Pizarro Sánchez Soledad13, Muñiz Rincón María14, Garcia-Fernández Nuria15, Blanco Castro Natalia16, Collantes Mateo Rocío17, Quiroz Morales Manuel Augusto18, Escamilla-Cabrera Beatriz19, Berdud Godoy Isabel20, Gil-Casares Casanova Beatriz21, Leyva Alba22, Rojas José22, Gansevoort Ron T23, de Sequera Patricia38, Carretero Marta Puerta, Tocora Daniel Gaitán, Rodríguez Mª Teresa Jaldo, Zanón Tamar Talaván, Suárez Esther Rodriguez, Santolaya Alfredo José Sáenz, Calero Raquel Cerrajero, Cobo Patricia Arribas, Ramos Patricia Muñoz, Gracia-Iguacel Carolina, Martin-Cleary Catalina, Sánchez-Rodríguez Jinny, Ramos-Verde Ana, Giraldo Yohana Gil, Suárez Pablo Ruano, Perpén Antonio Fernández, Ramos Andrés Fernández, Villanueva Laura Salanova, Cortiñas Alejandra, Díez Arias Pablo A, Cárdenas Alicia Cabrera, de Santos Antonio, Núñez Almudena, Cuadrado Guillermina Barril, Repollet Raquel, Moreso Francesc, Azancot María Antonieta, Ramos Natalia, Bestard Oriol, Cidraque Ignacio, Bermejo Sheila, Agraz Irene, Prat Oreto, Medina Carlota, Pardo Emma, Saiz Alejandro, Granados Nicolás Menéndez, Cabo María Jesús Corton, Alarcón Walter López, Alexandru Simona, Suarez Laura García Puente, Saico Saul Pampa, Tapia Marisol Poma, Osorio Laura Rodríguez, Zamora Rocío, Moreno Paloma Leticia Martin, González Noelia Ania, Ortiz Ana Sabalza, Iñarrea María Nieves Bastida, García Teresa, Narváez Carlos, Orellana Cristhian, León José Luis Pizarro, García Manuel Antonio Martínez, Jiménez Benaldina García, Moya Juan de Dios Ramiro, Espinosa Diana López, Herrador Alejandro Jiménez, Zurita Manuel Navarro, Álvarez Leonardo Díaz, Martínez Álvaro González, Arroyo Sandra Báez, Fernández Raquel Reina, Vargas Marlyn Janella Suárez, Casero Rocío Calurano, Useche Gustavo, de Miguel Carmen Santamaría, Palacios Ángel, Henningsmeyer Brenda, Calve Esther Orero, Moya José Lacueva, Gash Sandra Castellano, Martínez Lara Ruíz, De La Manzanara Perez Virginia Lopez, Arevalo Marta Calvo, Calvo Jose Antonio Herrero, Salgueira Mercedes, Aresté Nuria, de los Ángeles Rodríguez María, Collantes Rocío, Martínez Ana Isabel, Moyano María Jesús, Víbora Elena Jiménez, Hernández Aurelio Pastor Rodríguez, Rebollo María Sagrario García, Hernández Juana Margarita Rufino, Aguilera Esther Torres, Alea Rolando Tello, Del Rosario Saldaña Margie Soledad, de la Pisa Ana María Urraca, Monzon Lidia Sendino, Anachuri Karina Ampuero, Garcia Esther Hernández, Gomez Victoria Oviedo, Cavalotti Ignacio Manzur, Zorita Itziar Navarro, López Sol Otero, González Sara Outon, Montañez Carlos Soto, de Arellano Serna Manuel Ramírez, Perich Luis Guirado, de la Rosa Eva Cotilla,
Affiliation:
1. IIS-La Princesa, Nephrology Department, Hospital Universitario de la Princesa , Madrid , Spain 2. Nephrology Department, Vall d'Hebrón University Hospital , Barcelona , Spain 3. RICORS2040 (Kidney Disease) 4. IIS-Fundación Jiménez Diaz, School of Medicine, Universidad Autónoma de Madrid, Fundación Renal Iñigo Álvarez de Toledo-IRSIN, REDinREN, Instituto de Investigación Carlos III , Madrid , Spain 5. Diaverum Andalucía , Spain 6. Diaverum Valencia , Spain 7. Diaverum Castilla León-Galicia , Spain 8. Nephrology Department, Hospital Universitario Infanta Leonor – Universidad Complutense de Madrid , Madrid, Spain 9. Nephrology Department, Complejo Asistencial de Palencia , Palencia, Spain 10. Nephrology Department, Hospital Universitario Puerta del Mar , Cádiz , Spain 11. Nephrology Department, Hospital Da Mariña , Lugo , Spain 12. Nephrology Department, Hospital Universitario General de Villalba , Madrid, Spain 13. Nephrology Department, Hospital Rey Juan Carlos , Madrid , Spain 14. Nephrology Department, Hospital Clínico San Carlos , Madrid , Spain 15. Nephrology Department, Clínica Universidad de Navarra , Navarra , Spain 16. Nephrology Department , QuirónSalud A Coruña, A Coruña, Spain 17. Nephrology Department, Hospital Virgen de la Macarena , Sevilla , Spain 18. Nephrology Department , Consorci Sanitari Alt Penedès-Garraf, Barcelona , Spain 19. Nephrology Department, Hospital Universitario de Canarias , Canarias, Spain 20. FMC San Rafael , Córdoba , Spain 21. Nephrology Department, Hospital Universitario del Sureste , Madrid , Spain 22. R&D Department , VIRCELL SL, Granada , Spain 23. Dept Internal Medicine, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands
Abstract
ABSTRACT
Background
Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose.
Methods
This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed.
Results
A total of 711 patients [67% male, median age (range) 67 (20–89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001).
Conclusions
In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Funder
Fresenius Medical Care Diaverum Vifor Pharma Vircell Fundación Renal Iñigo Álvarez de Toledo ISCIII FEDER
Publisher
Oxford University Press (OUP)
Subject
Transplantation,Nephrology
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|